Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

Triplet combinations containing a proteasome inhibitor are a standard of care in newly diagnosed multiple myeloma (NDMM). We examined the long-term efficacy and safety of the all-oral combination of weekly ixazomib plus lenalidomide-dexamethasone (IRd), followed by single-agent ixazomib maintenance...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Shaji K., Berdeja, Jesus G., Niesvizky, Ruben, Lonial, Sagar, Laubach, Jacob P., Hamadani, Mehdi, Stewart, A. Keith, Hari, Parameswaran, Roy, Vivek, Vescio, Robert, Kaufman, Jonathan L., Berg, Deborah, Liao, Eileen, Rajkumar, S. Vincent, Richardson, Paul G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755968/
https://www.ncbi.nlm.nih.gov/pubmed/30696949
http://dx.doi.org/10.1038/s41375-019-0384-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755968/
https://www.ncbi.nlm.nih.gov/pubmed/30696949
http://dx.doi.org/10.1038/s41375-019-0384-1

Ejemplares similares